Literature DB >> 11157423

Therapeutic aspects of cannabis and cannabinoids.

P Robson1.   

Abstract

BACKGROUND: Review commissioned in 1996 by the Department of Health (DOH). AIMS: Assess therapeutic profile of cannabis and cannabinoids.
METHOD: Medline search, references supplied by DOH and others, and personal communications. RESULTS AND
CONCLUSIONS: Cannabis and some cannabinoids are effective anti-emetics and analgesics and reduce intra-ocular pressure. There is evidence of symptom relief and improved well-being in selected neurological conditions, AIDS and certain cancers. Cannabinoids may reduce anxiety and improve sleep. Anticonvulsant activity requires clarification. Other properties identified by basic research await evaluation. Standard treatments for many relevant disorders are unsatisfactory. Cannabis is safe in overdose but often produces unwanted effects, typically sedation, intoxication, clumsiness, dizziness, dry mouth, lowered blood pressure or increased heart rate. The discovery of specific receptors and natural ligands may lead to drug developments. Research is needed to optimise dose and route of administration, quantify therapeutic and adverse effects, and examine interactions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157423     DOI: 10.1192/bjp.178.2.107

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  51 in total

1.  Cannabis and the general practitioner--'going to pot'.

Authors:  Clare Gerada
Journal:  Br J Gen Pract       Date:  2003-08       Impact factor: 5.386

2.  Gene-environment interplay in affect and dementia: emotional modulation of cognitive expression in personal outcomes.

Authors:  T Palomo; R J Beninger; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 3.  Blurred boundaries: the therapeutics and politics of medical marijuana.

Authors:  J Michael Bostwick
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

4.  CB1 receptor-mediated signaling underlies the hippocampal synaptic, learning, and memory deficits following treatment with JWH-081, a new component of spice/K2 preparations.

Authors:  Balapal S Basavarajappa; Shivakumar Subbanna
Journal:  Hippocampus       Date:  2014-02       Impact factor: 3.899

5.  Cannabis and endocannabinoid modulators: Therapeutic promises and challenges.

Authors:  Igor Grant; B Rael Cahn
Journal:  Clin Neurosci Res       Date:  2005

6.  Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors.

Authors:  T V Zanelati; C Biojone; F A Moreira; F S Guimarães; Sâmia R L Joca
Journal:  Br J Pharmacol       Date:  2009-12-04       Impact factor: 8.739

7.  Pre-encoding administration of amphetamine or THC preferentially modulates emotional memory in humans.

Authors:  Michael E Ballard; David A Gallo; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2012-12-09       Impact factor: 4.530

Review 8.  Role of endocannabinoid system in mental diseases.

Authors:  Jorge Manzanares; Leyre Urigüen; Gabriel Rubio; Tomás Palomo
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 9.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

Review 10.  The therapeutic potential of cannabinoids for movement disorders.

Authors:  Benzi Kluger; Piera Triolo; Wallace Jones; Joseph Jankovic
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.